WSJ Buy Side is The Wall Street Journal’s research and commerce team. Our commerce content is distinct from our newsroom coverage. We earn a commission from some links in our articles. Learn more.

LOS ANGELES — All who walked into the Aliquippa High School football stadium, just outside of Pittsburgh, received a friendly greeting. “Welcome to the Pit” was hand-painted on the black shingles of ...

Thermo Fisher Scientific is launching a new test it says can help doctors avoid the “trial-and-error” approach typically used to dose patients with a common antirejection drug after organ transplant ...

Now 70, the victim of the shocking 1992 attack by her husband's teen mistress is narrating her shocking life story in Lifetime's 'I Am Mary Jo Buttafuoco' Janine Rubenstein is Editor-at-Large at ...

The morning of May 19, 1992, felt like any other for Mary Jo Buttafuoco. "I got the kids off to school, I cleaned the kitchen, I made the beds, I did all the mom stuff. And my plan that day was to ...

The Arknights: Endfield “Beta Test II” will begin on November 28 at 7:00 p.m. PT / 10:00 p.m. ET for PC, iOS, and Android, and the “PlayStation 5 Technical Test” featuring identical content will begin ...

The pending $23 billion sale of Madison-based Exact Sciences to health care giant Abbott centers on Exact Sciences' flagship product: colorectal cancer test Cologuard. Exact Sciences markets Cologuard ...

Abbott announced Thursday morning that it is acquiring Exact Sciences for $21 billion. The deal values Exact Sciences at $105 per share, representing a 22% premium to the cancer screening company’s ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Abbott is getting into cancer testing with its $21 billion acquisition Exact Sciences, the maker of the game-changing colorectal cancer test Cologuard. Abbott markets well-known diagnostics for ...

Abbott said on Thursday it would buy cancer test maker Exact Sciences in an up to $23 billion deal, bolstering the medical device maker's diagnostics business. This marks one of Abbott's largest deals ...

The acquisition will allow the diagnostics giant to enter the rapidly growing market for cancer tests Exact Sciences sells Cologuard, the at-home test for colorectal cancer that allows some patients ...